STE Stock Up on Q2 Earnings & Revenue Beat, '27 EPS View Up - Zacks Investment Research
STE Stock Up on Q2 Earnings & Revenue Beat, '27 EPS View Up - Zacks Investment Research(摘要待生成)
Compared to Estimates, Steris (STE) Q2 Earnings: A Look at Key Metrics - Zacks Investment Research
Compared to Estimates, Steris (STE) Q2 Earnings: A Look at Key Metrics - Zacks Investment Research(摘要待生成)
What STERIS (STE) Said on Its Q2 Earnings Call - Yahoo Finance
What STERIS (STE) Said on Its Q2 Earnings Call - Yahoo Finance(摘要待生成)
STERIS (STE) Q2 2027 Earnings Call Transcript
STERIS (STE) Q2 2027 Earnings Call Transcript(摘要待生成)
STERIS 8-K (2.02, 2.05, 9.01): reported results of operations
STERIS reported fiscal 2027 second-quarter revenue up 9% to $1.6 billion and adjusted diluted EPS of $2.94, raised its full-year adjusted EPS outlook to $11.35-$11.55, and approved a restructuring plan expected to cost about $45 million and save about $9 million annually.
Jefferies upgrades Steris stock rating on valuation, easing headwinds
Jefferies upgrades Steris stock rating on valuation, easing headwinds(摘要待生成)
STERIS 8-K (8.01, 9.01): other events
STERIS priced $1.5 billion of senior notes, including $750 million due 2033 at 5.650% and $750 million due 2036 at 5.875%, with proceeds intended to help fund its pending Xodus Medical acquisition and related costs.
STERIS 8-K (1.01, 1.02, 2.03, 9.01): entered into a material agreement
STERIS entered a $1.6 billion revolving credit agreement maturing November 4, 2031, replacing its 2024 facility without borrowing at closing, and the agreement allows up to $800 million in additional commitments.